Abstract 490P
Background
Breast cancer (BC) cells exploit the up-regulation or down-regulation of immune checkpoint molecules (ICM) to evade anti-tumor immune responses.ICMs can be measured in human plasma; however, their biological and clinical significance remains essentially unknown. The present analysis aimed to measure plasma ICMs in metastatic BC patients (pts) and compare them to healthy controls.
Methods
Soluble forms of ICM and RANTES, arginase, TGF-b1, CD163, and CD206 were measured using Multiplex® bead array and ELISA technologies. Plasma samples from 20 metastatic breast cancer (MBC) pts and 45 healthy controls were analyzed for each protein, and compared between MBC pts and healthy controls using a non-parametric test (Mann-Whitney).
Results
The median age of the cohort was 53 years (range 34-79 years). The performance status was as follows; PS=0 (11 pts), PS=1 (7 pts) and PS=2 (2 pts). The soluble co-stimulatory molecules, GITR (p<0.0011), GITRL (p< 0.0000), CD27 (p< 0.0039), CD28 (p<0.0069), CD40 (p< 0.0022), CD86 (p< 0.0000) and ICOS (p< 0.0157), as well as the co-inhibitory molecules, PD-L1 (p< 0.0002), CTLA-4 (p< 0.0002) and BTLA (p<0.0145) levels were significantly lower in MBC pts compared to healthy controls. Conversely, the co-inhibitory molecules, TIM-3 (p< 0.0001) and LAG-3 (p<0.0000 were significantly higher than those of healthy controls. Other biomarkers with raised plasma concentrations included TLR (p<0.0039). Plasma CD80 (p<0.0992), PD-1 (p<0.2325), HVEM (p<0.062,6), RANTES (p<0.4861) CD163 (p<0,8565) and CD206 (p<0,2454) levels were not significantly different between the MBC pts and the healthy controls.
Conclusions
We identified lower levels of CD27, CD28, CD40, ICOS, GITR, GITRL, CD86, PD-L1, CTLA-4, BTLA, arginase, and TGF-β1, and higher levels of TIM-3 and LAG-3 immune checkpoint molecules in MBC pts compared to healthy controls. These results indicate that a down-regulation of soluble ICM pathways and an up-regulation of some inhibitory ICM pathways are associated with MBC patients. To our knowledge, this is the first study to describe soluble immune checkpoint molecules in MBC pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
CANSA (Cancer Association of South Africa).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1288P - Neoadjuvant therapy with anti-PD-1/PD-L1 plus platinum-base chemotherapy for resectable stage II-III non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials
Presenter: Maria Dacoregio
Session: Poster session 04
1289TiP - LANTERN study: A multi-omics digital human avatar for integrating precision medicine into clinical practice for lung cancer patients
Presenter: Emilio Bria
Session: Poster session 04
1294P - A final analysis of a phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non–small-cell lung cancer: TORG1937 (DATE study)
Presenter: Tetsuro Kondo
Session: Poster session 04
1296P - Neoadjuvant camrelizumab and apatinib in patients with resectable non-small-cell lung cancer: One-year update from a phase II trial
Presenter: Wei Guo
Session: Poster session 04
1297P - An open-label, prospective phase II study of tislelizumab in combination with chidamide as consolidation therapy in locally advanced, unresectable, stage III NSCLC
Presenter: Yi Hu
Session: Poster session 04
1298P - Chemotherapy with concurrent proton vs. photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and immune therapy
Presenter: Francesco Cortiula
Session: Poster session 04
1299P - The role of radiotherapy in extensive-stage small cell lung cancer after durvalumab-based immunochemotherapy: A retrospective study
Presenter: Lingjuan Chen
Session: Poster session 04
1300P - Treatment and clinical outcome in recurrent/refractory locally advanced NSCLC following chemoradiotherapy and consolidative durvalumab
Presenter: Georg Evers
Session: Poster session 04